RESUMO
Immune checkpoint blockade is a hot spot in treatment of cancers recently,and their effi-cacy in digestive cancer cannot been ignored.Nivolumab is superior to sorafenib in the terms of prolonging survival period for the patients with advanced live cancer.The effective rate of Pembrolizumab for advanced PD-L1 positive expression esophageal cancer can reach 30%.Nevertheless,Ipilumumab shows no significant efficacy in advanced pancreatic carcinoma.More researches are on the way,such as Avelumab in advanced gastric cancer,and Pembrolizumab in advanced esophageal squamous carcinoma.
RESUMO
Tumor progression is often associated with immune suppression or the ability of the tumors to avoid immune surveillance.Immunotherapy improves the ability of the immune system to recognize and clear tumor cells with a little influence on the normal tissues.Immunotherapy is a hot spot in the research of advanced esophageal cancer.Innnunotherapy of esophageal cancer includes immune checkpoint inhibitors,adoptive cellular immunotherapy,tumor vaccines and antibody therapy.At present,a large number of clinical trials are underway to evaluate the role of immunotherapy in esophageal cancer.Checkpoint inhibitors represented by Pembrolizumab and Nivolumab,has achieved initial success in the treatment of advanced esophageal cancer to improve the prognosis and life quality of esophageal cancer patients.In the future,further studies are needed to have a research on the effects of tumor heterogeneity,prediction of therapeutic targets,and immune tolerance.
RESUMO
Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.